Publikationen

2025

• Ziegler, Anette-Gabriele; Achenbach, Peter; Weiß, Andreas; Berner, Reinhard; Casteels, Kristina; Elding Larsson, Helena; Haupt, Florian; Hommel, Angela; Jacobs, An; Kordonouri, Olga; Lundgren, Markus; Ołtarzewski, Mariusz; Pfirrmann, Markus; Snape, Matthew D.; Szypowska, Agnieszka; Todd, John A.; Vatish, Manu; Berge, Thekla von dem; Winkler, Christiane; Bonifacio, Ezio; Casteels, Kristina; Houben, Janne; Jacobs, An; Jannsen, Charlien; Morobé, Hilde; Paulus, Jasmin; Rochtus, Anne; Driessche, Natalie Van den; Heyste, Renka Van; Vanhuyse, Veerle; Vrancken, Brontë; Arabi, Sari; Berner, Reinhard; Blechschmidt, Ruth; Bonifacio, Ezio (2025)
  Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial
  In: Lancet, Vol. 406, Nr. 10519: S. 2564-2576 (Volltext vorhanden)
  
• Lauseker, Michael; Hoffmann, Verena S.; Pfirrmann, Markus (2025)
  Prognostic scoring systems in chronic myeloid leukaemia
  In: Leukemia, Vol. 39, Nr. 5: S. 1046-1052 (Volltext vorhanden)
  
• Hummel, Sandra; Käßl, Alexandra; Arnolds, Stefanie; Achenbach, Peter; Berner, Reinhard; Casteels, Kristina; Hyöty, Heikki; Kordonouri, Olga; Larsson, Helena Elding; Lundgren, Markus; Marcovecchio, M. Loredana; Owen, Catherine; Pfirrmann, Markus; Robson, Steve; Szadkowska, Agnieszka; Szypowska, Agnieszka; Tree, Timothy; Weiss, Andreas; Ziegler, Anette-Gabriele; Bonifacio, Ezio (2025)
  Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocol
  In: Contemporary Clinical Trials Communications, Vol. 44 (Volltext vorhanden)
  

nach oben

2024

• Efficace, Fabio; Mahon, Francois-Xavier; Richter, Johan; Piciocchi, Alfonso; Cipriani, Marta; Nicolini, Franck E.; Mayer, Jiri; Zackova, Daniela; Janssen, Jeroen J. W. M.; Panayiotidis, Panayiotis; Vestergaard, Hanne; Koskenvesa, Perttu; Almeida, Antonio; Hjorth-Hansen, Henrik; Martinez-Lopez, Joaquin; Olsson-Strömberg, Ulla; Hochhaus, Andreas; Berger, Marc G.; Etienne, Gabriel; Klamova, Hana; Faber, Edgar; Rousselot, Philippe; Pfirrmann, Markus; Saussele, Susanne (2024)
  Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
  In: Leukemia, Vol. 38, Nr. 8: S. 1722-1730
  
• Brioli, Annamaria; Lomaia, Elza; Fabisch, Christian; Sacha, Tomasz; Klamova, Hana; Morozova, Elena; Golos, Aleksandra; Ernst, Philipp; Olsson-Stromberg, Ulla; Zackova, Daniela; Nicolini, Franck E.; Bao, Han; Castagnetti, Fausto; Patkowska, Elzbieta; Mayer, Jiri; Hirschbühl, Klaus; Podgornik, Helena; Paczkowska, Edyta; Parry, Anne; Ernst, Thomas; Voskanyan, Astghik; Szczepanek, Elzbieta; Saussele, Susanne; Franke, Georg-Nikolaus; Kiani, Alexander; Faber, Edgar; Krause, Stefan; Casado, Luis Felipe; Lewandowski, Krzysztof; Eder, Matthias; Anhut, Peter; Gil, Justyna; Südhoff, Thomas; Hebart, Holger; Heibl, Sonja; Pfirrmann, Markus; Hochhaus, Andreas; Lauseker, Michael (2024)
  Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
  In: Leukemia, Vol. 38: S. 1072-1080 (Volltext vorhanden)
  
• Mahon, Francois-Xavier; Pfirrmann, Markus; Dulucq, Stéphanie; Hochhaus, Andreas; Panayiotidis, Panayiotis; Almeida, Antonio; Mayer, Jiri; Hjorth-Hansen, Henrik; Janssen, Jeroen J.W.M.; Mustjoki, Satu; Martinez-Lopez, Joaquin; Vestergaard, Hanne; Ehrencrona, Hans; Machová Poláková, Katerina; Olsson-Strömberg, Ulla; Ossenkoppele, Gert; Berger, Marc G.; Etienne, Gabriel; Dengler, Jolanta; Brümmendorf, Tim H.; Burchert, Andreas; Réa, Delphine; Rousselot, Philippe; Nicolini, Franck E.; Hofmann, Wolf-Karsten; Richter, Johan; Saussele, Susanne; Mayer, Jiri; Voglová, Jaroslava; Faber, Edgar; Klamova, Hana; Vestergaard, Hanne; Koskenvesa, Perttu; Mahon, Francois-Xavier; Etienne, Gabriel; Berger, Marc G.; Rousselot, Philippe; Nicolini, Franck E.; Charbonnier, Aude; Legros, Laurence; Réa, Delphine; Guilhot, François; Escoffre-Barbe, Martine; Huguet, Françoise; Gyan, Emmanuel; Brümmendorf, Tim Henrik; Waller, Cornelius; Dengler, Jolanta; Hochhaus, Andreas; Saußele, Susanne; Burchert, Andreas; Kunzmann, Volker; Pagoni, Maria N.; Panayiotidis, Panayiotis; Janssen, Jeroen J.W.M.; Ossenkoppele, Gert; Westerweel, Peter E.; Greef, Georgine E. de; Gruber, Franz; Hjorth-Hansen, Henrik; Almeida, Antonio; Martinez-Lopez, Joaquin; Lotfi, Kourosh; Richter, Johan; Stenke, Leif; Olsson-Strömberg, Ulla; Söderlund, Stina (2024)
  European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
  In: Journal of Clinical Oncology, Vol. 42, Nr. 16: S. 1875-1880 (Volltext vorhanden)
  
• Pfirrmann, Markus; Saussele, Susanne; Mahon, François-Xavier; Richter, Johan (2024)
  How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen
  In: Leukemia, Vol. 38, Nr. 2: S. 460-462 (Volltext vorhanden)
  

nach oben

2023

• Machova Polakova, Katerina; Albeer, Ali; Polivkova, Vaclava; Krutska, Monika; Vlcanova, Katerina; Curik, Nikola; Fabarius, Alice; Klamova, Hana; Spiess, Birgit; Waller, Cornelius F.; Brümmendorf, Tim H.; Dengler, Jolanta; Kunzmann, Volker; Burchert, Andreas; Belohlavkova, Petra; Mustjoki, Satu; Faber, Edgar; Mayer, Jiri; Zackova, Daniela; Panayiotidis, Panayiotis; Richter, Johan; Hjorth-Hansen, Henrik; Kamińska, Magdalena; Płonka, Magdalena; Szczepanek, Elżbieta; Szarejko, Monika; Bober, Grażyna; Hus, Iwona; Grzybowska-Izydorczyk, Olga; Wasilewska, Ewa; Paczkowska, Edyta; Niesiobędzka-Krężel, Joanna; Giannopoulos, Krzysztof; Mahon, Francois X.; Sacha, Tomasz; Saußele, Susanne; Pfirrmann, Markus (2023)
  The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
  In: Leukemia, Vol. 38: S. 318-325 (Volltext vorhanden)
  
• Niederwieser, Dietger; Lang, Thomas; Krahl, Rainer; Heinicke, Thomas; Maschmeyer, Georg; Al-Ali, Haifa Kathrin; Schwind, Sebastian; Jentzsch, Madlen; Cross, Michael; Kahl, Christoph; Wolf, Hans-Heinrich; Sayer, Herbert; Schulze, Antje; Dreger, Peter; Hegenbart, Ute; Krämer, Alwin; Junghanss, Christian; Mügge, Lars-Olof; Hähling, Detlev; Hirt, Carsten; Späth, Christian; Peter, Norma; Opitz, Bernhard; Florschütz, Axel; Reifenrath, Kolja; Zojer, Niklas; Scholl, Sebastian; Pönisch, Wolfram; Heyn, Simone; Vucinic, Vladan; Hochhaus, Andreas; Aul, Carlo; Giagounidis, Aristoteles; Balleisen, Leopold; Oldenkott, Bernd; Staib, Peter; Kiehl, Michael; Schütte, Wolfgang; Naumann, Ralph; Eimermacher, Hartmut; Dörken, Bernd; Sauerland, Cristina; Lengfelder, Eva; Hiddemann, Wolfgang; Wörmann, Bernhard; Müller-Tidow, Carsten; Serve, Hubert; Schliemann, Christoph; Hehlmann, Rüdiger; Berdel, Wolfgang E.; Pfirrmann, Markus; Krug, Utz; Hoffmann, Verena S. (2023)
  Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
  In: Annals of Hematology, Vol. 102: S. 547-561 (Volltext vorhanden)
  
• Bornhäuser, Martin; Schliemann, Christoph; Schetelig, Johannes; Röllig, Christoph; Kramer, Michael; Glass, Bertram; Platzbecker, Uwe; Burchert, Andreas; Hänel, Mathias; Müller, Lutz P.; Klein, Stefan; Bug, Gesine; Beelen, Dietrich; Rösler, Wolf; Schäfer-Eckart, Kerstin; Schmid, Christoph; Jost, Edgar; Lenz, Georg; Tischer, Johanna; Spiekermann, Karsten; Pfirrmann, Markus; Serve, Hubert; Stölzel, Friedrich; Alakel, Nael; Middeke, Jan Moritz; Thiede, Christian; Ehninger, Gerhard; Berdel, Wolfgang E.; Stelljes, Matthias (2023)
  Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia
  In: JAMA Oncology, Vol. 9, Nr. 4: S. 519-526
  
• Isfort, Susanne; Manz, Kirsi; Teichmann, Lino L.; Crysandt, Martina; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Kiani, Alexander; Göthert, Joachim R.; Illmer, Thomas; Schafhausen, Philippe; Al-Ali, Haifa Kathrin; Stegelmann, Frank; Hänel, Mathias; Pfeiffer, Tim; Giagounidis, Aristoteles; Franke, Georg-Nikolaus; Koschmieder, Steffen; Fabarius, Alice; Ernst, Thomas; Warnken-Uhlich, Mareille; Wolber, Uta; Kohn, Denise; Pfirrmann, Markus; Wolf, Dominik; Brümmendorf, Tim H. (2023)
  Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
  In: Annals of Hematology, Vol. 102: S. 2741-2752 (Volltext vorhanden)
  

nach oben

2022

• Schönfeld, Lioba; Rinke, Jenny; Hinze, Anna; Nagel, Saskia N.; Schäfer, Vivien; Schenk, Thomas; Fabisch, Christian; Brümmendorf, Tim H.; Burchert, Andreas; Coutre, Philipp le; Krause, Stefan W.; Saussele, Susanne; Safizadeh, Fatemeh; Pfirrmann, Markus; Hochhaus, Andreas; Ernst, Thomas (2022)
  ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
  In: Leukemia, Vol. 36: S. 2242-2249 (Volltext vorhanden)
  
• Völk, Stefanie; Pfirrmann, Markus; Koedel, Uwe; Pfister, Hans-Walter; Lang, Thomas; Scheibe, Franziska; Salih, Farid; Herzig-Nichtweiss, Julia; Zimmermann, Julian; Alonso, Angelika; Wittstock, Matthias; Totzeck, Andreas; Schramm, Patrick; Schirotzek, Ingo; Onur, Oezguer A.; Pelz, Johann Otto; Ottomeyer, Caroline; Luger, Sebastian; Barlinn, Kristian; Binder, Tobias; Wöbker, Gabriele; Reimann, Gernot; Urbanek, Christian; Heckelmann, Jan; Lochner, Piergiorgio; Berghoff, Martin; Schönenberger, Silvia; Neumann, Bernhard; Niesen, Wolf-Dirk; Dohmen, Christian; Huttner, Hagen B.; Günther, Albrecht; Klein, Matthias (2022)
  Decline in the number of patients with meningitis in German hospitals during the COVID-19 pandemic
  In: Journal of Neurology, Vol. 269: S. 3389-3399 (Volltext vorhanden)
  

nach oben

2021

• Masouris, Ilias; Manz, Kirsi; Pfirrmann, Markus; Dreyling, Martin; Angele, Barbara; Straube, Andreas; Langer, Sigrid; Huber, Marion; Koedel, Uwe; Baumgarten, Louisa von (2021)
  CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma-Diagnostic, Therapeutic, and Prognostic Relevance
  In: Frontiers in Neurology, Vol. 12 (Volltext vorhanden)
  
• Ziegler, Anette-Gabriele; Arnolds, Stefanie; Hasford, Joerg; Kordonouri, Olga; Lundgren, Markus; Oltarzewski, Mariusz; Pekalski, Marcin L.; Pfirrmann, Markus; Snape, Matthew D.; Szypowska, Agnieszka; Todd, John A. (2021)
  Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity. The GPPAD-SINT1A randomised controlled trial protocol
  In: BMJ Open, Vol. 11, Nr. 11 (Volltext vorhanden)
  
• Egeli, Damla Buket; Hanfstein, Benjamin; Lauseker, Michael; Pfirrmann, Markus; Saussele, Susanne; Baerlocher, Gabriela M.; Müller, Martin C. (2021)
  SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment
  In: Leukemia & Lymphoma: S. 1-8
  
• Assfalg, Robin; Knoop, Jan; Hoffman, Kristi L.; Pfirrmann, Markus; Zapardiel-Gonzalo, Jose Maria; Hofelich, Anna; Eugster, Anne; Weigelt, Marc; Matzke, Claudia; Reinhardt, Julia; Fuchs, Yannick; Bunk, Melanie; Weiss, Andreas; Hippich, Markus; Halfter, Kathrin; Hauck, Stefanie M.; Hasford, Jörg; Petrosino, Joseph F.; Achenbach, Peter; Bonifacio, Ezio; Ziegler, Anette-Gabriele (2021)
  Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial
  In: Diabetologia, Vol. 64, Nr. 5: S. 1079-1092 (Volltext vorhanden)
  
• Egeli, Damla Buket; Hanfstein, Benjamin; Lauseker, Michael; Pfirrmann, Markus; Saussele, Susanne; Baerlocher, Gabriela M.; Müller, Martin C. (2021)
  SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment
  In: Leukemia & Lymphoma, Vol. 63, Nr. 4: S. 955-962
  
• Ziegler, Anette-Gabriele; Arnolds, Stefanie; Kolln, Annika; Achenbach, Peter; Berner, Reinhard; Bonifacio, Ezio; Casteels, Kristina; Elding Larsson, Helena; Gundert, Melanie; Hasford, Joerg; Kordonouri, Olga; Lundgren, Markus; Oltarzewski, Mariusz; Pekalski, Marcin L.; Pfirrmann, Markus; Snape, Matthew D.; Szypowska, Agnieszka; Todd, John A. (2021)
  Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol
  In: BMJ Open, Vol. 11, Nr. 11
  
• Assfalg, Robin; Knoop, Jan; Hoffman, Kristi L.; Pfirrmann, Markus; Zapardiel-Gonzalo, Jose Maria; Hofelich, Anna; Eugster, Anne; Weigelt, Marc; Matzke, Claudia; Reinhardt, Julia; Fuchs, Yannick; Bunk, Melanie; Weiss, Andreas; Hippich, Markus; Halfter, Kathrin; Hauck, Stefanie M.; Hasford, Jörg; Petrosino, Joseph F.; Achenbach, Peter; Bonifacio, Ezio; Ziegler, Anette-Gabriele (2021)
  Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial
  In: Diabetologia, Vol. 64, Nr. 5: S. 1079-1092
  

nach oben

2020

• Brioli, Annamaria; Manz, Kirsi; Pfirrmann, Markus; Hänel, Mathias; Schwarzer, Andreas Christoph; Prange-Krex, Gabriele; Fabisch, Christian; Knop, Stefan; Illmer, Thomas; Krammer-Steiner, Beate; Hochhaus, Andreas; Lilienfeld-Toal, Marie von; Mügge, Lars-Olof (2020)
  Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)
  In: Journal of cancer research and clinical oncology, Vol. 146, Nr. 3: S. 749-759
  
• Hehlmann, Rüdiger; Voskanyan, Astghik; Lauseker, Michael; Pfirrmann, Markus (2020)
  Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
  In: Leukemia, Vol. 34, Nr. 10
  
• Lange, Thoralf; Niederwieser, Christian; Gil, Arthur; Krahl, Rainer; von Grünhagen, Ulrich; Deininger, Michael; Pfirrmann, Markus; Niederwieser, Dietger (2020)
  No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group
  In: Leukemia & Lymphoma, Vol. 61, Nr. 12: S. 2821-2830
  
• Pfirrmann, Markus; Clark, Richard E.; Prejzner, Witold; Lauseker, Michael; Baccarani, Michele; Saussele, Susanne; Guilhot, François; Hasford, Joerg; Hochhaus, Andreas; Hoffmann, Verena S. (2020)
  The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
  In: Leukemia, Vol. 34, Nr. 8: S. 2138-2149 (Volltext vorhanden)
  
• Hehlmann, Rüdiger; Voskanyan, Astghik; Lauseker, Michael; Pfirrmann, Markus; Hasford, Jörg; Kolb, Hans-Jochem (2020)
  High-risk additional chromosomal abnormalities at low blast counts herald death by CML
  In: Leukemia, Vol. 34: S. 2074-2086 (Volltext vorhanden)
  

nach oben

2019

• Lauseker, Michael; Bachl, Katharina; Turkina, Anna; Faber, Edgar; Prejzner, Witold; Olsson-Strömberg, Ulla; Baccarani, Michele; Lomaia, Elza; Zackova, Daniela; Ossenkoppele, Gert; Griskevicius, Laimonas; Schubert-Fritschle, Gabriele; Sacha, Tomasz; Heibl, Sonja; Koskenvesa, Perttu; Bogdanovic, Andrija; Clark, Richard E.; Guilhot, Joelle; Hoffmann, Verena S.; Hasford, Joerg; Hochhaus, Andreas; Pfirrmann, Markus (2019)
  Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
  In: American Journal of Hematology, Vol. 94, Nr. 11: S. 1236-1243 (Volltext vorhanden)
  
• Michel, Christian; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Neubauer, Andreas; Lauseker, Michael; Krause, Stefan W.; Kolb, Hans-Jochem; Hossfeld, Dieter Kurt; Nerl, Christoph; Baerlocher, Gabriela M.; Heim, Dominik; Brümmendorf, Alice and Haferlach; Pfirrmann, Markus (2019)
  Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
  In: Haematologica, Vol. 104, Nr. 5: S. 955-962
  
• Baccarani, Michele; Castagnetti, Fausto; Gugliotta, Gabriele; Rosti, Gianantonio; Soverini, Simona; Albeer, Ali; Pfirrmann, Markus (2019)
  The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
  In: Leukemia, Vol. 33, Nr. 5: S. 1173-1183
  

nach oben

2018

• Rinaldetti, Sébastien; Pfirrmann, Markus; Manz, Kirsi; Guilhot, Joelle; Dietz, Christian; Panagiotidis, Panayiotidis; Spiess, Birgit; Seifarth, Wolfgang; Fabarius, Alice; Müller, Martin; Pagoni, Maria; Dimou, Maria; Dengler, Jolanta; Waller, Cornelius F.; Brümmendorf, Tim H.; Herbst, Regina; Burchert, Andreas; Janßen, Carsten; Goebeler, Maria Elisabeth; Jost, Philipp J.; Hanzel, Stefan; Schafhausen, Philippe; Prange-Krex, Gabriele; Illmer, Thomas; Janzen, Viktor; Klausmann, Martine; Eckert, Robert; Büschel, Gerd; Kiani, Alexander; Hofmann, Wolf-Karsten; Mahon, François-Xavier; Saussele, Susanne (2018)
  Effect of ABCG2, OCT1, and ABCB1(MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
  In: Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, Nr. 4: S. 266-271 (Volltext vorhanden)
  
• Hummel, Sandra; Beyerlein, Andreas; Pfirrmann, Markus; Hofelich, Anna; Much, Daniela; Hivner, Susanne; Bunk, Melanie; Herbst, Melanie; Peplow, Claudia; Walter, Markus; Kohn, Denise; Hummel, Nadine; Kratzsch, Jürgen; Hasford, Joerg; Ziegler, Anette-G.; Hummel, Michael; Füchtenbusch, Martin (2018)
  Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study
  In: Molecular Metabolism, Vol. 9: S. 168-175
  
• Saussele, Susanne; Richter, Johan; Guilhot, Joelle; Gruber, Franz X.; Hjorth-Hansen, Henrik; Almeida, Antonio; Janssen, Jeroen J. W. M.; Mayer, Jiri; Koskenvesa, Perttu; Panayiotidis, Panayiotis; Olsson-Strömberg, Ulla; Martinez-Lopez, Joaquin; Rousselot, Philippe; Vestergaard, Hanne; Ehrencrona, Hans; Kairisto, Veli; Machová Poláková, Katerina; Müller, Martin C.; Mustjoki, Satu; Berger, Marc G.; Fabarius, Alice; Hofmann, Wolf-Karsten; Hochhaus, Andreas; Pfirrmann, Markus; Mahon, Francois-Xavier (2018)
  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial
  In: The Lancet, Vol. 19, Nr. 6: S. 747-757
  
• Saussele, Susanne; Hehlmann, Rüdiger; Fabarius, Alice; Jeromin, Sabine; Proetel, Ulrike; Rinaldetti, Sebastien; Kohlbrenner, Katharina; Einsele, Hermann; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Oppliger Leibundgut, Elisabeth; Heim, Dominik; Krause, Stefan W.; Hofmann, Wolf-Karsten; Hasford, Joerg; Pfirrmann, Markus; Müller, Martin C.; Hochhaus, Andreas; Lauseker, Michael (2018)
  Defining therapy goals for major molecular remission in chronic myeloid leukemia: Results of the randomized CML Study IV
  In: Leukemia, Vol. 32, Nr. 5: S. 1222-1228 (Volltext vorhanden)
  
• Schütz, C.; Inselmann, S.; Saussele, Susanne; Dietz, C. T.; Müller, M. C.; Eigendorff, E.; Brendel, C. A.; Metzelder, S. K.; Brümmendorf, T. H.; Waller, C.; Dengler, J.; Goebeler, M. E.; Herbst, R.; Freunek, G.; Hanzel, S.; Illmer, Thomas; Wang, Y.; Lange, T.; Finkernagel, F.; Hehlmann, Rüdiger; Huber, M.; Neubauer, A.; Hochhaus, Andreas; Guilhot, Joelle; Mahon, F. X.; Pfirrmann, Markus; Burchert, A. (2018)
  Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
  In: Leukemia, Vol. 32, Nr. 4
  
• Rupprecht, Tobias Armin; Manz, Kirsi Marjaana; Fingerle, Volker; Lechner, Christian; Klein, Matthias; Pfirrmann, Markus; Koedel, Uwe (2018)
  Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systemic review and meta-analysis
  In: Clinical Microbiology and infection
  
• Drube, Julia; Ernst, Thomas; Pfirrmann, Markus; Albert, Benadict Vincent; Drube, Sebastian; Reich, Daniela; Kresinsky, Anne; Halfter, Kathrin; Sorio, Claudio; Fabisch, Christian; Hochhaus, Andreas; Böhmer, Frank-D (2018)
  PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
  In: Oncotarget, Vol. 9, Nr. 10: S. 9442-9455
  

nach oben

2017

• Pfirrmann, Markus; Evtimova, D.; Saussele, S.; Castagnetti, F.; Cervantes, F.; Janssen, Jan; Hoffmann, Verena; Gugliotta, G.; Hehlmann, R.; Hochhaus, A.; Hasford, Joerg; Baccarani, M. (2017)
  No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib
  In: Journal of Cancer Research and Clinical Oncology, Vol. 143, Nr. 5: S. 843-850
  
• Rinaldetti, S.; Sticht, C.; Pfirrmann, Markus; Nowak, Dennis; Fabarius, A.; Seifarth, W.; Spiess, B.; Felde, E.; Tarnopolskaja, I.; Hölting, C.; Nowak, V.; Panayiotidis, P.; Pagoni, M.; Dimou, M.; Dengler, J.; Waller, C. F.; Brümmendorf, T. H.; Burchert, A.; Freunek, G.; Büschel, G.; Göbeler, M. E.; Klausmann, M.; Herbst, R.; Hanzel, S.; Schafhausen, P.; Hofmann, W.-K.; Mahon, F.-X.; Saussele, S. (2017)
  The EUROSKI biomarker study: analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia
  In: Oncology Research and Treatment, Vol. 40, Nr. Suppl. 5: S. 120-121
  
• Hehlmann, Rüdiger; Lauseker, Michael; Saußele, Susanne; Hochhaus, Andreas; Hasford, Joerg; Pfirrmann, Markus; Kolb, Hans-Jochem; Spiekermann, Karsten; Fabarius, Alice; Müller, M. C.; Proetel, Ulrike; Kohlbrenner, K.; Voskanyan, A.; Rinaldetti, S.; Seifarth, W.; Spieß, B.; Krause, S. W.; Neubauer, A.; Burchert, A.; Hossfeld, Dieter K.; Schafhausen, P.; Nerl, C.; Gratwohl, A.; Heim, D.; Baerlocher, Gabriela M.; Brümmendorf, Tim H.; Fuchs, R.; Haferlach, C.; Jeromin, S.; Schlegelberger, Brigitte; Balleisen, L.; Goebeler, M. C.; Hänel, M.; Ho, A.; Dengler, J.; Falge, C.; Kanz, L.; Kremers, S.; Kneba, M.; Stegelmann, F.; Köhne, C. A.; Lindemann, H. W.; Waller, C. F.; Pfreundschuh, Michael; Berdel, Wolfgang E.; Müller, L.; Edinger, M.; Mayer, J.; Beelen, D. W.; Bentz, M.; Link, H.; Hertenstein, Bernd; Wernli, Martin; Schlegel, F.; Schlag, R.; Wit, M. de; Trumper, L.; Hebart, H.; Hahn, M.; Thomalla, J.; Scheid, C.; Verbeek, W.; Eckart, M. J.; Gassmann, W.; Pezzutto, A.; Schenk, M.; Brossart, P.; Geer, T.; Bildat, S.; Schäfer, E. (2017)
  Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
  In: Leukemia, Vol. 31, Nr. 11: S. 2398-2406
  
• Schütz, C.; Inselmann, S.; Saussele, Susanne; Dietz, C. T.; Müller, M. C.; Brendel, C. A.; Metzelder, S. K.; Brümmendorf, Tim H.; Waller, C.; Dengler, J.; Goebeler, M. E.; Herbst, R.; Hanzel, S.; Freunek, G.; Illmer, T.; Wang, Y.; Lange, T.; Finkernagel, F.; Hehlmann, R.; Huber, M.; Neubauer, A.; Hochhaus, A.; Guilhot, J.; Xavier Mahon, F.; Pfirrmann, Markus; Burchert, A. (2017)
  Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
  In: Leukemia, Vol. 31: S. 829-836
  
• Lauseker, Michael; Hasford, Joerg; Saussele, Susanne; Kremers, Stephan; Kraemer, Doris; Lindemann, Walter; Hehlmann, Rüdiger; Pfirrmann, Markus (2017)
  Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death
  In: Cancer, Vol. 123, Nr. 13: S. 2467-2471
  

nach oben

2016

• Pfirrmann, Markus; Baccarani, M.; Saußele, Susanne; Guilhot, J.; Cervantes, F.; Ossenkoppele, G.; Hoffmann, V. S.; Castagnetti, F.; Hasford, Joerg; Hehlmann, R.; Simonsson, B. (2016)
  Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
  In: Leukemia, Vol. 30, Nr. 1: S. 48-56
  
• Gratwohl, A.; Pfirrmann, Markus; Zander, A.; Kröger, N.; Beelen, D.; Novotny, J.; Nerl, C.; Scheid, C.; Spiekermann, Karsten; Mayer, J.; Sayer, H. G.; Falge, C.; Bunjes, D.; Döhner, H.; Ganser, A.; Schmidt-Wolf, I.; Schwerdtfeger, R.; Baurmann, H.; Kuse, R.; Schmitz, N.; Wehmeier, A.; Fischer, J. T.; Ho, A. D.; Wilhelm, M.; Goebeler, M. E.; Lindemann, H. W.; Bormann, M.; Hertenstein, B.; Schlimok, G.; Baerlocher, Gabriela M.; Aul, C.; Pfreundschuh, M.; Fabian, M.; Staib, P.; Edinger, M.; Schatz, M.; Fauser, A.; Arnold, R.; Kindler, T.; Wulf, G.; Rosselet, A.; Hellmann, A.; Schäfer, E.; Prümmer, O.; Schenk, M.; Hasford, Joerg; Heimpel, H.; Hossfeld, D. K.; Kolb, H.-J.; Büsche, G.; Haferlach, C.; Schnittger, S.; Müller, M. C.; Reiter, A.; Berger, Ute; Saußele, Susanne; Hochhaus, A.; Hehlmann, R. (2016)
  Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
  In: Leukemia, Vol. 30, Nr. 3: S. 562-569
  
• Jawhar, M.; Schwaab, J.; Schnittger, S.; Meggendorfer, M.; Pfirrmann, Markus; Sotlar, K.; Horny, H. P.; Metzgeroth, G.; Kluger, S.; Naumann, N.; Haferlach, C.; Haferlach, T.; Valent, P.; Hofmann, W. K.; Fabarius, A.; Cross, N. C.; Reiter, A. (2016)
  Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis
  In: Leukemia, Vol. 30, Nr. 1: S. 136-143
  
• Miranda, M. B.; Lauseker, Michael; Kraus, M. P.; Proetel, U.; Hanfstein, B.; Fabarius, A.; Baerlocher, Gabriela M.; Heim, D.; Hossfeld, D. K.; Kolb, H. J.; Krause, S. W.; Nerl, C.; Brümmendorf, Tim H.; Verbeek, W.; Fauser, A. A.; Prummer, O.; Neben, K.; Hess, U.; Mahlberg, R.; Ploger, C.; Flasshove, M.; Rendenbach, B.; Hofmann, W. K.; Muller, M. C.; Pfirrmann, Markus; Hochhaus, A.; Hasford, Joerg; Hehlmann, R.; Saußele, Susanne (2016)
  Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
  In: Leukemia, Vol. 30, Nr. 6: S. 1255-1262
  

nach oben

2015

• Fabarius, A.; Kalmanti, L.; Dietz, C. T.; Lauseker, Michael; Rinaldetti, S.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Jotterand, M.; Hanfstein, B.; Seifarth, W.; Hänel, M.; Köhne, C. H.; Lindemann, H. W.; Berdel, W. E.; Staib, P.; Müller, M. C.; Proetel, U.; Balleisen, L.; Goebeler, M. E.; Dengler, J.; Falge, C.; Kanz, L.; Burchert, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Brümmendorf, Tim H.; Edinger, M.; Hofmann, W. K.; Pfirrmann, Markus; Hasford, Joerg; Krause, S.; Hochhaus, A.; Saußele, Susanne; Hehlmann, R. (2015)
  Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
  In: Annals of Hematology, Vol. 94, Nr. 12: S. 2015-2024
  
• Kalmanti, L.; Saußele, Susanne; Lauseker, Michael; Muller, M. C.; Dietz, C. T.; Heinrich, L.; Hanfstein, B.; Proetel, U.; Fabarius, A.; Krause, S. W.; Rinaldetti, S.; Dengler, J.; Falge, C.; Oppliger-Leibundgut, E.; Burchert, A.; Neubauer, A.; Kanz, L.; Stegelmann, F.; Pfreundschuh, M.; Spiekermann, Karsten; Scheid, C.; Pfirrmann, Markus; Hochhaus, A.; Hasford, Joerg; Hehlmann, R. (2015)
  Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
  In: Leukemia, Vol. 29, Nr. 5: S. 1123-1132
  
• Saußele, Susanne; Krauß, M. P.; Hehlmann, R.; Lauseker, Michael; Proetel, U.; Kalmanti, L.; Hanfstein, B.; Fabarius, A.; Kraemer, D.; Berdel, W. E.; Bentz, M.; Staib, P.; de Wit, M.; Wernli, M.; Zettl, F.; Hebart, H. F.; Hahn, M.; Heymanns, J.; Schmidt-Wolf, I.; Schmitz, N.; Eckart, M. J.; Gassmann, W.; Bartholomäus, A.; Pezzutto, A.; Oppliger Leibundgut, E.; Heim, D.; Krause, S. W.; Burchert, A.; Hofmann, W. K.; Hasford, Joerg; Hochhaus, A.; Pfirrmann, Markus; Müller, M. C. (2015)
  Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV
  In: Blood, Vol. 126, Nr. 1: S. 42-49
  
• Lauseker, Michael; Hasford, Joerg; Hoffmann, V. S.; Mueller, M. C.; Hehlmann, R.; Pfirrmann, Markus (2015)
  A multi-state model approach for prediction in chronic myeloid leukaemia
  In: Annals of Hematology, Vol. 94, Nr. 6: S. 919-927
  
• Pfirrmann, Markus; Lauseker, Michael; Hoffmann, V. S.; Hasford, Joerg (2015)
  Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death
  In: Annals of Hematology / Supplements, Vol. 94, Nr. 2: S. S209-18
  

nach oben

2014

• Lauseker, Michael; Hanfstein, Benjamin; Haferlach, Claudia; Schnittger, Susanne; Pfirrmann, Markus; Fabarius, Alice; Schlegelberger, Brigitte; Saußele, Susanne; Dietz, Christian T.; Erben, Philipp; Hehlmann, Rüdiger; Hasford, Joerg; Hochhaus, Andreas; Müller, Martin C. (2014)
  Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase
  In: Journal of cancer research and clinical oncology, Vol. 140, Nr. 11: S. 1965-1969
  
• Hanfstein, B.; Shlyakhto, V.; Lauseker, Michael; Hehlmann, R.; Saussele, S.; Dietz, C. T.; Erben, P.; Fabarius, A.; Proetel, U.; Schnittger, S.; Krause, S. W.; Schubert, J.; Einsele, H.; Hänel, M.; Dengler, J.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, K.; Baerlocher, G. M.; Pfirrmann, Markus; Hasford, Joerg; Hofmann, W. K.; Hochhaus, A.; Muller, M. C. (2014)
  Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
  In: Leukemia, Vol. 28, Nr. 10: S. 1988-1992
  
• Hehlmann, Rüdiger; Hasford, Joerg; Pfirrmann, Markus; Lauseker, Michael; Saußele, Susanne; Hochhaus, Andreas (2014)
  Reply to H. Kantarjian et al.
  In: Journal of Clinical Oncology, Vol. 32, Nr. 27
  
• Pfirrmann, Markus; Saussele, S.; Hochhaus, A.; Reiter, A.; Berger, U.; Hossfeld, D. K.; Nerl, C.; Scheid, C.; Spiekermann, K.; Mayer, J.; Hellmann, A.; Lechner, K.; Falge, C.; Sayer, H. G.; Bunjes, D.; Ganser, A.; Beelen, D. W.; Baldomero, H.; Schanz, U.; Heimpel, H.; Kolb, H. J.; Hasford, Joerg; Gratwohl, A.; Hehlmann, R. (2014)
  Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia
  In: Journal of Cancer Research and Clinical Oncology, Vol. 140, Nr. 8: S. 1367-1381
  
• Proetel, Ulrike; Pletsch, Nadine; Lauseker, Michael; Müller, Martin C.; Hanfstein, Benjamin; Krause, Stefan W.; Kalmanti, Lida; Schreiber, Annette; Heim, Dominik; Baerlocher, Gabriela M.; Hofmann, Wolf-Karsten; Lange, Elisabeth; Einsele, Hermann; Wernli, Martin; Kremers, Stephan; Schlag, Rudolf; Müller, Lothar; Hänel, Mathias; Link, Hartmut; Hertenstein, Bernd; Pfirrmann, Markus; Hochhaus, Andreas; Hasford, Joerg; Hehlmann, Rüdiger; Saußele, Susanne (2014)
  Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
  In: Annals of Hematology, Vol. 93, Nr. 7: S. 1167-1176 (Volltext vorhanden)
  
• Lauseker, Michael; Hasford, Joerg; Pfirrmann, Markus; Hehlmann, Rüdiger (2014)
  The impact of health care settings on survival time of patients with chronic myeloid leukemia
  In: Blood, Vol. 123, Nr. 16: S. 2494-2496
  
• Hehlmann, R.; Müller, M. C.; Lauseker, Michael; Hanfstein, B.; Fabarius, A.; Schreiber, A.; Proetel, U.; Pletsch, N.; Pfirrmann, Markus; Haferlach, C.; Schnittger, S.; Einsele, H.; Dengler, J.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Ehninger, G.; Heim, D.; Heimpel, H.; Nerl, C.; Krause, S. W.; Hossfeld, D. K.; Kolb, H. J.; Hasford, Joerg; Saußele, Susanne; Hochhaus, A. (2014)
  Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
  In: Journal of Clinical Oncology, Vol. 32, Nr. 5: S. 415-423
  
• Hanfstein, Benjamin; Lauseker, Michael; Hehlmann, Rüdiger; Saussele, Susanne; Erben, Philipp; Dietz, Christian; Fabarius, Alice; Proetel, Ulrike; Schnittger, Susanne; Haferlach, Claudia; Krause, Stefan W.; Schubert, Joerg; Einsele, Hermann; Hänel, Mathias; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Pfirrmann, Markus; Hasford, Jörg; Hofmann, Wolf-Karsten; Hochhaus, Andreas; Müller, Martin C. (2014)
  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
  In: Haematologica, Vol. 99, Nr. 9: S. 1441-1447 (Volltext vorhanden)
  
• Kalmanti, L.; Saußele, Susanne; Lauseker, Michael; Proetel, U.; Muller, M. C.; Hanfstein, B.; Schreiber, A.; Fabarius, A.; Pfirrmann, Markus; Schnittger, S.; Dengler, J.; Falge, C.; Kanz, L.; Neubauer, A.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Krause, S. W.; Heim, D.; Nerl, C.; Hossfeld, D. K.; Kolb, H. J.; Hochhaus, A.; Hasford, Joerg; Hehlmann, R. (2014)
  Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
  In: Annals of Hematology, Vol. 93, Nr. 1: S. 71-80
  

nach oben

2013

• Lange, T.; Ernst, T.; Gruber, F.; Maier, J.; Cross, M.; Müller, M. C.; Niederwieser, D. W.; Hochhaus, A.; Pfirrmann, Markus (2013)
  The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia
  In: Haematologica, Vol. 98, Nr. 5: S. 714-717
  
• Schwaab, J.; Schnittger, S.; Sotlar, K.; Walz, C.; Fabarius, A.; Pfirrmann, Markus; Kohlmann, A.; Grossmann, V.; Meggendorfer, M.; Horny, H. P.; Valent, P.; Jawhar, M.; Teichmann, M.; Metzgeroth, G.; Erben, P.; Ernst, T.; Hochhaus, A.; Haferlach, T.; Hofmann, W. K.; Cross, N. C.; Reiter, A. (2013)
  Comprehensive mutational profiling in advanced systemic mastocytosis
  In: Blood, Vol. 122, Nr. 14: S. 2460-2466
  
• Hoffmann, V. S.; Baccarani, M.; Lindörfer, Doris; Castagnetti, F.; Turkina, A.; Zaritsky, A.; Hellmann, A.; Prejzner, W.; Steegmann, J. L.; Mayer, J.; Indrak, K.; Colita, A.; Rosti, G.; Pfirrmann, Markus (2013)
  The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
  In: Leukemia, Vol. 27, Nr. 10: S. 2016-2022
  

nach oben

2012

• Lauseker, Michael; Pfirrmann, Markus; Hoffmann, V. S.; Hasford, Joerg (2012)
  Comment On “Second-Generation Tyrosine Kinase Inhibitors Improve The Survival Of Patients With Chronic Myeloid Leukemia In Whom Imatinib Therapy Has Failed” Haematologica 2011;96(12):1779–82
  In: Haematologica, Vol. 97, Nr. 5
  
• Hoffmann, Verena; Baccarani, M.; Hasford, Joerg; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus; Hehlmann, R. (2012)
  The EUTOS CML score aims to support clinical decision-making
  In: Blood, Vol. 119, Nr. 12: S. 2966-2967
  
• Büchner, T.; Schlenk, R. F.; Schaich, M.; Doehner, K.; Krahl, R.; Krauter, J.; Heil, G.; Krug, U.; Sauerland, M. C.; Heinecke, A.; Späth, Daniela; Kramer, M.; Scholl, S.; Berdel, W. E.; Hiddemann, Wolfgang; Hoelzer, D.; Hehlmann, R.; Hasford, Joerg; Hoffmann, V. S.; Doehner, H.; Ehninger, G.; Ganser, A.; Niederwieser, D. W.; Pfirrmann, Markus (2012)
  Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm‐Combined Prospective Analysis by the German AML Intergroup
  In: Journal of Clinical Oncology, Vol. 30, Nr. 29: S. 3604-3610
  
• Saußele, Susanne; Pfirrmann, Markus (2012)
  Clinical Trials in Chronic Myeloid Leukemia
  In: Current Hematologic Malignancy Reports, Vol. 7, Nr. 2: S. 109-115
  
• Hanfstein, B.; Müller, M. C.; Hehlmann, R.; Erben, P.; Lauseker, Michael; Fabarius, A.; Schnittger, S.; Haferlach, C.; Göhring, G.; Proetel, U.; Kolb, H. J.; Krause, S. W.; Hofmann, W. K.; Schubert, J.; Einsele, H.; Dengler, J.; Hänel, M.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Branford, S.; Hughes, T. P.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Pfirrmann, Markus; Hasford, Joerg; Saußele, Susanne; Hochhaus, A. (2012)
  Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
  In: Leukemia, Vol. 26, Nr. 9: S. 2096-2102
  
• Pfirrmann, Markus; Ehninger, G.; Thiede, C.; Bornhäuser, M.; Kramer, M.; Röllig, C.; Hasford, Joerg; Schaich, M. (2012)
  Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial
  In: Lancet Oncology, Vol. 13, Nr. 2: S. 207-214
  

nach oben

2011

• Stoelzel, F.; Pfirrmann, Markus; Aulitzky, W. E.; Kaufmann, M.; Bodenstein, H.; Bornhäuser, M.; Roellig, C.; Kramer, M.; Mohr, B.; Oelschlaegel, U.; Schmitz, N.; Soucek, S.; Thiede, C.; Ehninger, G.; Schaich, M. (2011)
  Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial
  In: Leukemia, Vol. 25, Nr. 3: S. 420-428
  
• Pfirrmann, Markus; Hochhaus, A.; Lauseker, Michael; Saußele, Susanne; Hehlmann, R.; Hasford, Joerg (2011)
  Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia
  In: Leukemia, Vol. 25, Nr. 9: S. 1433-1438
  
• Fabarius, A.; Leitner, A.; Hochhaus, A.; Müller, M. C.; Hanfstein, B.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Jotterand, M.; Reiter, A.; Jung-Munkwitz, S.; Proetel, U.; Schwaab, J.; Hofmann, W. K.; Schubert, J.; Einsele, H.; Ho, A. D.; Falge, C.; Kanz, L.; Neubauer, A.; Kneba, M.; Stegelmann, F.; Pfreundschuh, M.; Waller, C. F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Lauseker, Michael; Pfirrmann, Markus; Hasford, Joerg; Saußele, Susanne; Hehlmann, R. (2011)
  Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV
  In: Blood, Vol. 118, Nr. 26: S. 6760-6768
  
• Pfirrmann, Markus (2011)
  Statistisches Testen in der Onkologie
  In: Onkologe, Der, Vol. 17, Nr. 4: S. 337-348
  
• Hasford, Joerg; Baccarani, M.; Hoffmann, Verena; Guilhot, J.; Saußele, Susanne; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindörfer, Doris; Simonsson, B.; Pfirrmann, Markus; Hehlmann, R. (2011)
  Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
  In: Blood, Vol. 118, Nr. 3: S. 686-692
  
• Hehlmann, R.; Lauseker, Michael; Jung-Munkwitz, S.; Leitner, A.; Müller, M. C.; Pletsch, N.; Proetel, U.; Haferlach, C.; Schlegelberger, B.; Balleisen, L.; Hänel, M.; Pfirrmann, Markus; Krause, S. W.; Nerl, C.; Pralle, H.; Gratwohl, A.; Hossfeld, D. K.; Hasford, Joerg; Hochhaus, A.; Saußele, Susanne (2011)
  Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia
  In: Journal of Clinical Oncology, Vol. 29, Nr. 12: S. 1634-1642
  

nach oben

2010

• Saußele, Susanne; Lauseker, Michael; Gratwohl, A.; Beelen, D. W.; Bunjes, D.; Schwerdtfeger, R.; Kolb, H. J.; Ho, A. D.; Falge, C.; Holler, E.; Schlimok, G.; Zander, A. R.; Arnold, R.; Kanz, L.; Dengler, R.; Haferlach, C.; Schlegelberger, B.; Pfirrmann, Markus; Müller, M. C.; Schnittger, S.; Leitner, A.; Pletsch, N.; Hochhaus, A.; Hasford, Joerg; Hehlmann, R. (2010)
  Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
  In: Blood, Vol. 115, Nr. 10: S. 1880-1885
  

nach oben

2009

• Bruegger, D.; Rehm, M.; Abicht, J.; Paul, J. O.; Stoeckelhuber, M.; Pfirrmann, Markus; Reichart, B.; Becker, B. F.; Christ, F. (2009)
  Shedding of the endothelial glycocalyx during cardiac surgery: On-pump versus off-pump coronary artery bypass graft surgery
  In: Journal of Thoracic and Cardiovascular Surgery, Vol. 138, Nr. 6: S. 1445-1447
  
• Ernst, T.; Gruber, F. X.; Pelz-Ackermann, O.; Maier, J.; Pfirrmann, Markus; Muller, M. C.; Mikkola, I.; Porkka, K.; Niederwieser, D. W.; Hochhaus, A.; Lange, T. (2009)
  A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib
  In: Haematologica, Vol. 94, Nr. 9: S. 1227-1235
  
• Schaich, M.; Kestel, L.; Pfirrmann, Markus; Robel, K.; Illmer, T.; Kramer, M.; Dill, C.; Ehninger, G.; Schackert, G.; Krex, D. (2009)
  A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients
  In: Annals of Oncology, Vol. 20, Nr. 1: S. 175-181
  

nach oben

2007

• Kreil, S.; Pfirrmann, Markus; Haferlach, C.; Waghorn, K.; Chase, A.; Hehlmann, R.; Reiter, A.; Hochhaus, A.; Cross, NC. (2007)
  Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia
  In: Blood, Vol. 110, Nr. 4: S. 1283-1290
  
• Hehlmann, R.; Berger, Ursula; Pfirrmann, Markus; Heimpel, H.; Hochhaus, A.; Hasford, Joerg; Kolb, H. J.; Lahaye, T.; Maywald, O.; Reiter, A.; Hossfeld, D. K.; Huber, C.; Löffler, H.; Pralle, H.; Queisser, W.; Tobler, A.; Nerl, C.; Solenthaler, M.; Goebeler, M. E.; Grieshammer, M.; Fischer, T.; Kremers, S.; Eimermacher, H.; Pfreundschuh, M.; Hirschmann, W. D..; Lechner, K.; Wassmann, B.; Falge, C.; Kirchner, H. H..; Gratwohl, A. (2007)
  Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia
  In: Blood, Vol. 109, Nr. 11: S. 4686-4692
  

nach oben

2006

• Maywald, O.; Pfirrmann, Markus; Berger, Ursula; Breitscheidel, L.; Gratwohl, A.; Kolb, H. J.; Beelen, D. W.; Tobler, A.; Metzgeroth, G.; Gnad, S. U.; Hochhaus, A.; Hasford, Joerg; Hehlmann, R.; Reiter, A. (2006)
  Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia
  In: Leukemia, Vol. 20, Nr. 3: S. 477-484
  

nach oben

2005

• Hasford, Joerg; Pfirrmann, Markus; Hochhaus, A. (2005)
  How long will chronic myeloid leukemia patients treated with imatinib mesylate live?
  In: Leukemia, Vol. 19, Nr. 4: S. 497-499
  
• Hasford, Joerg; Pfirrmann, Markus; Shepherd, P.; Guilhot, J.; Hehlmann, R.; Mahon, F. X.; Kluin-Nelemans, H. C.; Ohnishi, K.; Steegmann, J. L.; Thaler, J. (2005)
  The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha
  In: Haematologica, Vol. 90, Nr. 3: S. 335-340
  
• Pfirrmann, Markus; Hasford, Joerg (2005)
  A simulation study using validated prognostic factors to assess expected long-term survival
  In: Methods of Information in Medicine, Vol. 44, Nr. 4: S. 577-583
  
• Berger, Ursula; Maywald, O.; Pfirrmann, Markus; Lahaye, T.; Hochhaus, A.; Reiter, A.; Hasford, Joerg; Heimpel, H.; Hossfeld, D. K.; Kolb, H. J.; Löffler, H.; Pralle, H.; Queisser, W.; Hehlmann, R.; Kolb, H.-J. (2005)
  Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
  In: Leukemia, Vol. 19, Nr. 6: S. 984-989
  

nach oben

2004

• Lenz, G.; Dreyling, Martin; Schiegnitz, E.; Forstpointner, R.; Wandt, H.; Freund, M.; Hess, G.; Truemper, L.; Diehl, V.; Kropff, M.; Kneba, M.; Schmitz, N.; Metzner, B.; Pfirrmann, Markus; Unterhalt, Michael; Hiddemann, Wolfgang (2004)
  Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group
  In: Blood, Vol. 104, Nr. 9: S. 2667-2674
  
• Buesche, G.; Freund, M.; Hehlmann, R.; Georgii, A.; Ganser, A.; Hecker, H.; Heimpel, H.; Fonatsch, C.; Heinze, B.; Pfirrmann, Markus; Holgado, S.; Schmeil, A.; Tobler, A.; Hasford, Joerg; Buhr, T.; Kreipe, H. H. (2004)
  Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia
  In: Leukemia, Vol. 18, Nr. 9: S. 1460-1467
  

nach oben

2003

• Hehlmann, R.; Berger, Ursula; Pfirrmann, Markus; Hochhaus, A.; Metzgeroth, G.; Maywald, O.; Hasford, Joerg; Reiter, A.; Hossfeld, D. K.; Kolb, H. J.; Löffler, H.; Pralle, H.; Queisser, W.; Griesshammer, M.; Nerl, C.; Kuse, R.; Tobler, A.; Eimermacher, H.; Tichelli, A.; Aul, C.; Wilhelm, M.; Fischer, J. T.; Perker, M.; Scheid, C.; Schenk, M.; Weiss, J.; Meier, C. R.; Kremers, S.; Labedzki, L.; Schmeiser, T.; Lohrmann, H. P.; Heimpel, H.; Kolb, H.-J.; Lohrmann, H.-P. (2003)
  Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea
  In: Leukemia, Vol. 17, Nr. 8: S. 1529-1537
  
• Buesche, G.; Hehlmann, R.; Hecker, H.; Heimpel, H.; Heinze, B.; Schmeil, A.; Pfirrmann, Markus; Gomez, G.; Tobler, A.; Herrmann, H.; Kappler, M.; Hasford, Joerg; Buhr, T.; Kreipe, H. H.; Georgii, A. (2003)
  Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial
  In: Leukemia, Vol. 17, Nr. 12: S. 2444-2453
  
• Hasford, Joerg; Pfirrmann, Markus; Hehlmann, R.; Baccarani, M.; Guilhot, F.; Mahon, F. X.; Kluin-Nelemans, H. C.; Ohnishi, K.; Thaler, J.; Steegmann, J. L. (2003)
  Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy
  In: Seminars in Hematology, Vol. 40, Nr. 1: S. 4-12
  
• Berger, Ursula; Engelich, G.; Maywald, O.; Pfirrmann, Markus; Hochhaus, A.; Reiter, A.; Metzgeroth, G.; Gnad, U.; Hasford, Joerg; Heinze, B.; Heimpel, H.; Hossfeld, D. K.; Kolb, H.-J.; Löffler, H.; Pralle, H.; Queisser, W.; Hehlmann, R. (2003)
  Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha
  In: Leukemia, Vol. 17, Nr. 9: S. 1820-1826
  

nach oben

2001

• Pfirrmann, Markus; Hasford, Joerg (2001)
  Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Comments
  In: British Journal of Haematology, Vol. 114, Nr. 1: S. 241-243
  

nach oben

1999

• Hehlmann, Rüdiger; Hochhaus, Andreas; Kolb, Hans-Jochem; Hasford, Joerg; Gratwohl, Alois; Heimpel, Hermann; Siegert, Wolfgang; Finke, Jürgen; Ehninger, Gerhard; Holler, Ernst; Berger, Ute; Pfirrmann, Markus; Muth, Alexander; Zander, Alex; Fauser, Axel A.; Heyll, Axel; Nerl, Christoph; Hossfeld, Dieter K.; Löffler, Helmut; Pralle, Hans; Queißer, Wolfgang; Tobler, Andreas (1999)
  Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure
  In: Blood, Vol. 94, Nr. 11: S. 3668-3677
  

nach oben

1998

• Hasford, Joerg; Pfirrmann, Markus; Hehlmann, R.; Allan, N. C.; Baccarani, M.; Kluin-Nelemans, J. C.; Alimena, G.; Steegmann, J. L.; Ansari, H. (1998)
  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group
  In: Journal of the National Cancer Institute, Vol. 90, Nr. 11: S. 850-859
  

nach oben

1996

• Hasford, Joerg; Ansari, H.; Pfirrmann, Markus; Hehlmann, Rüdiger (1996)
  Analysis and validation of prognostic factors for CML
  In: Bone Marrow Transplantation, Vol. 17, Nr. Supplement 3: S. 49-54